HMOX1 and chronic myelogenous leukemia, BCR-ABL1 positive: These data are also in line with our previous observations that Hsp32 inhibitors block the growth of imatinib-resistant CML cells as well as Ba/F3 cells expressing various imatinib-resistant mutants of BCR/ABL1, including the T315I mutant that renders BCR/ABL1 resistant against all currently available BCR/ABL1 TKI [29].